SVRA

Savara Inc. (SVRA) | Rumor.io

Savara

SVRA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,883

Bullish sentiment (50-day avg)100%

Price to earnings ratio-9.58

Market capitalization1B

Earnings per share-0.58

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-118.8M

Social

What share of all stock conversation is about SVRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Feb 21

$SVRA surged +3% after hours on FDA priority review news for its lung disorder therapy Molbreevi, indicating a potential catalyst for the stock.
The FDA's priority review for Molbreevi is a key regulatory milestone, but traders should exercise caution and await confirmation of the move through volume and price action.
Technical resistance levels are being tested, and traders should monitor the stock's performance for a potential durable momentum shift or a bull trap.

Generated by AI

Sentiment

Of the messages about SVRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	92.89% +5.54
Bearish	0%	0%	0% 0	7.11% -5.54

Bullish· Jun 26

$SVRA has met its primary endpoint in the Phase 3 IMPALA-2 clinical trial, showing a statistically significant improvement in lung function.
The company has received positive analyst opinions, with Oppenheimer maintaining an Outperform rating and raising the price target to $15, and Jefferies predicting a 50-100% stock move possible after the trial success.
$SVRA has shown strong market momentum, surging 61% premarket and hitting 30% gains, with analysts predicting a further run and upgraded price targets expected to be announced.

Bearish· Jun 26

$SVRA is experiencing a significant price drop, down 22.91% in the last 16 minutes, following positive news from the Phase 3 IMPALA-2 trial.
The stock's behavior may be influenced by a large number of shares available to short, potentially contributing to the price decline.
The company's recent news and positive trial results have not been enough to sustain the stock's price, with some investors describing the selling as "inevitable" and a "short run bullshit".

Generated by AI

Topics

Of the messages about SVRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	70.12%
Analysts	—	0%	0%	14.73%
Controversies	—	0%	0%	0.41%
Earnings	—	0%	0%	0.62%
Macro	—	0%	0%	5.81%
Technical Analysis	—	0%	0%	8.3%

Earnings· Nov 8

Savara Inc. ($SVRA) reported a narrower-than-expected loss per share, beating EPS estimates by $0.30.
This earnings beat is a positive development for the company, potentially boosting investor sentiment.
The company's ability to narrow its loss per share suggests potential for future earnings growth.

Analysts· Jun 13

Canaccord Genuity maintains a Buy rating for Savara Inc. ($SVRA) with a PT of $15, following a previous PT of $22.
HC Wainwright lowered Savara Inc.'s ($SVRA) PT to $6.00, while maintaining a Buy rating.
Analysts at Ladenburg Thalmann downgraded Savara Inc. ($SVRA) to Neutral with a PT of $3, while analysts at JMP Securities lowered their rating to Market Perform.

Announcements· May 27

Savara Inc. received a Refusal to File (RTF) letter from the FDA for the Biologics License Application (BLA) of Molbreevi, a therapy to treat autoimmune pulmonary alveolar proteinosis.
The FDA's decision was due to incomplete data on manufacturing and controls, and not a result of safety concerns or a request for additional efficacy studies.
Savara intends to request a Type A meeting with the FDA within 30 days and expects to resubmit the BLA in Q4 2025 with Fujifilm as the supplier.

Technical Analysis· Mar 16

SVRA has formed a cup and handle pattern on the 1H chart, indicating a potential bullish trend.
A key short-term indicator to watch for SVRA is the volume-weighted average price (VWAP), which may hold as a short-term resistance level.
SVRA's stock price is trading above the 200-day moving average, suggesting a bullish sentiment, and may retest the $2.60 area as support.

Generated by AI

Community

Of the messages about SVRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0.94%	0.39%	40.56%
Newcomers	100%	99.06%	99.61%	59.44%

Regulars· Jun 26

Savara announces that its lead asset, Molgramostim Nebulizer Solution, has achieved statistical significance for its primary endpoint and multiple secondary endpoints in the IMPALA-2 Phase 3 clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
The company plans to host an investor call to discuss the top-line results from the IMPALA-2 trial, which will take place on June 26, 2024, at 8:00am ET.
The positive results from the trial have led to a surge in Savara's stock price, with a gain of over 28% and a peak sales estimate of $300M assuming a $300k price tag and 1k patients.

Newcomers· Feb 21

The FDA has granted priority review for Savara's (SVRA) lung disorder therapy Molbreevi, leading to a 3%+ after-hours surge in the stock.
The stock's after-hours move suggests that options flow is active and technical support levels are being tested, prompting caution and risk management.
The FDA's priority review decision is a major catalyst for SVRA, but its sustainability is uncertain, and traders are advised to await confirmation via volume and price action before taking any action.

Generated by AI

YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.

1mo agoYahoo Finance

Savara Announces New Employment Inducement Grant

YARDLEY, Pa., August 20, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees.

1mo agoYahoo Finance

Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)

Detailed price information for Savara Inc (SVRA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Guggenheim Remains a Buy on Savara (SVRA)

Detailed price information for Savara Inc (SVRA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

LANGHORNE, Pa., August 11, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update.

1mo agoYahoo Finance

Also Discussed

Investors talking about SVRA also mention

#	Name	Attention
1	Opus Genetics Inc.OCUP	0%0
2	Corgi All Commodities 2x Daily ETFXCOM	0%0
3	Axe Compute Inc.POAI	0%new
4	Palatin Technologies, Inc.PTN	0%0
5	NAVB - Navidea Biopharmaceuticals, Inc.	——
6	CDMO - Avid Bioservices, Inc.	——
7	U.S. Gold Corp.USAU	0%0
8	Delcath Systems, Inc.DCTH	0%new
9	Vislink Technologies Inc.VISL	0%0
10	DarkHorse Technologies Inc.ANY	0%new

Savara Inc.

Healthcare
Biotechnology

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis. Its lead product candidate, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor being advanced through late-stage clinical development. Savara’s current business is concentrated on research, clinical development, and regulatory progress in orphan and specialty respiratory medicine, rather than on a broad commercial product portfolio. The company serves a niche market within biotechnology and pharmaceuticals, where expertise in pulmonary medicine and rare disease development is central to its role.

Website

Location

1717 Langhorne Newtown Road

Langhorne, PA, 19047

United States

Social

What share of all stock conversation is about SVRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Feb 21

$SVRA surged +3% after hours on FDA priority review news for its lung disorder therapy Molbreevi, indicating a potential catalyst for the stock.
The FDA's priority review for Molbreevi is a key regulatory milestone, but traders should exercise caution and await confirmation of the move through volume and price action.
Technical resistance levels are being tested, and traders should monitor the stock's performance for a potential durable momentum shift or a bull trap.

Generated by AI

Sentiment

Of the messages about SVRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	92.89% +5.54
Bearish	0%	0%	0% 0	7.11% -5.54

Bullish· Jun 26

$SVRA has met its primary endpoint in the Phase 3 IMPALA-2 clinical trial, showing a statistically significant improvement in lung function.
The company has received positive analyst opinions, with Oppenheimer maintaining an Outperform rating and raising the price target to $15, and Jefferies predicting a 50-100% stock move possible after the trial success.
$SVRA has shown strong market momentum, surging 61% premarket and hitting 30% gains, with analysts predicting a further run and upgraded price targets expected to be announced.

Bearish· Jun 26

$SVRA is experiencing a significant price drop, down 22.91% in the last 16 minutes, following positive news from the Phase 3 IMPALA-2 trial.
The stock's behavior may be influenced by a large number of shares available to short, potentially contributing to the price decline.
The company's recent news and positive trial results have not been enough to sustain the stock's price, with some investors describing the selling as "inevitable" and a "short run bullshit".

Generated by AI

Topics

Of the messages about SVRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	70.12%
Analysts	—	0%	0%	14.73%
Controversies	—	0%	0%	0.41%
Earnings	—	0%	0%	0.62%
Macro	—	0%	0%	5.81%
Technical Analysis	—	0%	0%	8.3%

Earnings· Nov 8

Savara Inc. ($SVRA) reported a narrower-than-expected loss per share, beating EPS estimates by $0.30.
This earnings beat is a positive development for the company, potentially boosting investor sentiment.
The company's ability to narrow its loss per share suggests potential for future earnings growth.

Analysts· Jun 13

Canaccord Genuity maintains a Buy rating for Savara Inc. ($SVRA) with a PT of $15, following a previous PT of $22.
HC Wainwright lowered Savara Inc.'s ($SVRA) PT to $6.00, while maintaining a Buy rating.
Analysts at Ladenburg Thalmann downgraded Savara Inc. ($SVRA) to Neutral with a PT of $3, while analysts at JMP Securities lowered their rating to Market Perform.

Announcements· May 27

Savara Inc. received a Refusal to File (RTF) letter from the FDA for the Biologics License Application (BLA) of Molbreevi, a therapy to treat autoimmune pulmonary alveolar proteinosis.
The FDA's decision was due to incomplete data on manufacturing and controls, and not a result of safety concerns or a request for additional efficacy studies.
Savara intends to request a Type A meeting with the FDA within 30 days and expects to resubmit the BLA in Q4 2025 with Fujifilm as the supplier.

Technical Analysis· Mar 16

SVRA has formed a cup and handle pattern on the 1H chart, indicating a potential bullish trend.
A key short-term indicator to watch for SVRA is the volume-weighted average price (VWAP), which may hold as a short-term resistance level.
SVRA's stock price is trading above the 200-day moving average, suggesting a bullish sentiment, and may retest the $2.60 area as support.

Generated by AI

Community

Of the messages about SVRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0.94%	0.39%	40.56%
Newcomers	100%	99.06%	99.61%	59.44%

Regulars· Jun 26

Savara announces that its lead asset, Molgramostim Nebulizer Solution, has achieved statistical significance for its primary endpoint and multiple secondary endpoints in the IMPALA-2 Phase 3 clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
The company plans to host an investor call to discuss the top-line results from the IMPALA-2 trial, which will take place on June 26, 2024, at 8:00am ET.
The positive results from the trial have led to a surge in Savara's stock price, with a gain of over 28% and a peak sales estimate of $300M assuming a $300k price tag and 1k patients.

Newcomers· Feb 21

The FDA has granted priority review for Savara's (SVRA) lung disorder therapy Molbreevi, leading to a 3%+ after-hours surge in the stock.
The stock's after-hours move suggests that options flow is active and technical support levels are being tested, prompting caution and risk management.
The FDA's priority review decision is a major catalyst for SVRA, but its sustainability is uncertain, and traders are advised to await confirmation via volume and price action before taking any action.

Generated by AI

Savara

Social

Feb 21

Bullish· Jun 26

Bearish· Jun 26

Earnings· Nov 8

Analysts· Jun 13

Announcements· May 27

Technical Analysis· Mar 16

Regulars· Jun 26

Newcomers· Feb 21

Savara presents molgramostim data at ERS Congress in September

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Announces New Employment Inducement Grant

Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)

Guggenheim Remains a Buy on Savara (SVRA)

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Savara Inc.

Company Information

Location

Savara presents molgramostim data at ERS Congress in September

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Announces New Employment Inducement Grant

Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA)

Guggenheim Remains a Buy on Savara (SVRA)

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Also Discussed

Social

Feb 21

Bullish· Jun 26

Bearish· Jun 26

Earnings· Nov 8

Analysts· Jun 13

Announcements· May 27

Technical Analysis· Mar 16

Regulars· Jun 26

Newcomers· Feb 21